Zenas BioPharma, Inc. (ZBIO) Stock Price, Financials & Summary

Price chart

Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29

Key dataOct 29, 2026

Open$29.08

From 52W high−33.31%

Volume372590.00

Market cap$1.88B

P/E (TTM)—

P/S (TTM)1876.4x

Div yield—

Key dataOct 29, 2026

Open

$29.08

From 52W high

−33.31%

Volume

372590.00

Market cap

$1.88B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.5x

P/E (TTM)

—

RSI (14)

54.0

MomentumView details →

1D Return

+0.07%

YTD Return

−20.94%

SummaryUpdated Jun 1, 2026

Zenas BioPharma, Inc. (NASDAQ:ZBIO) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Waltham, Massachusetts. The company went public in September 2024 through an initial public offering. Zenas focuses on developing transformative immunology-based therapies for autoimmune and inflammatory diseases, with its lead product candidate obexelimab currently in clinical trials for multiple indications including rare autoimmune conditions and multiple sclerosis.

Ask drillr about Zenas BioPharma, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−3.5x

EV/Sales

1622.9x

P/S (TTM)

1876.4x

P/B (TTM)

7.6x

ProfitabilityView details →

Gross Margin

−5972.60%

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−196.03%

ROA (TTM)

−69.03%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−93.33%

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

−55.28%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+0.07%

YTD Return

−20.94%

1Y Return

−3.93%

RSI (14)

54.0

vs 50D SMA

−2.83%

vs 200D SMA

+15.16%

Capital & dividendView details →

Debt/Equity

1.58x

Current Ratio

9.93x

Quick Ratio

9.93x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.77

EPS Surprise

−58.04%

Beats (12Q)

1/12

Next Q EPS Est

−$1.11

Avg Surprise (4Q)

−114.55%

Rev Surprise

−93.33%

Financials snapshotView financials →

Revenue (TTM)

1.00M

Net Income (TTM)

−484.38M

Op. CF (TTM)

−225.97M

Next earningsNov 18, 2026 →

Latest newsMore news →

Zenas BioPharma announced it will host a virtual R&D event on October 27, 2026.24d ago

Zenas BioPharma announced upcoming presentations of obexelimab data in IgG4-related disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026.38d ago

Similar companies

Mineralys Therapeutics, Inc.MLYS *ST海利603718.SH Intellia Therapeutics, Inc.NTLA Mind Medicine (MindMed) Inc.MNMD Braveheart Bio, Inc.BRVE Galapagos N.V.GLPG Find similar companies →

Latest newsMore news →

Zenas BioPharma announced it will host a virtual R&D event on October 27, 2026.24d ago Zenas BioPharma announced upcoming presentations of obexelimab data in IgG4-related disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026.38d ago